Skyward Specialty Announces Secondary Offering of Its Common Stock
HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) — Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a […]
Stellantis Pro One Achieves No. 1 Spot in Middle East & Africa Region and Strengthens Commercial Vehicle Leadership in Europe and South America
Stellantis Pro One Achieves No. 1 Spot in Middle East & Africa Region and Strengthens Commercial Vehicle Leadership in Europe […]
AMG Reports Financial and Operating Results for the First Quarter of 2024
Company reports EPS of $4.14, Economic EPS of $5.37 in first quarter Net Income (controlling interest) of $150 million, Economic […]
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 […]
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to […]
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment […]
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a […]
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic […]
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of […]
TSX News -
KP Tissue Announces Filing and Mailing of the Management Proxy Materials in Connection with its 2024 Annual Meeting of Shareholders
Your vote is important no matter how many shares you own. Vote today. Shareholders who have questions or need assistance […]
